Semaglutide vs Telmisartan

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

SemaglutideTelmisartan
CategoryPharmaceuticalsPharmaceuticals
Standard DoseResearch indicates 0.25 mg weekly SC for 4 weeks, escalating to 0.5 mg, then 1.0 mg, then 1.7 mg, then 2.4 mg weekly (FDA weight management protocol). Oral: 3 mg daily for 30 days, then 7 mg, then 14 mg daily.
TimingSC injection any time of day, with or without food, on the same day each week. Oral: take on empty stomach with no more than 4 oz water, 30+ minutes before first food/drink/medications.
Cycle DurationLong-term/continuous use. Weight regain occurs upon discontinuation (67% regain within 1 year in trials).
Evidence LevelStrong (FDA-approved)Strong
A

Semaglutide

Pharmaceuticals

Mechanism

Semaglutide is a GLP-1 receptor agonist with 94% structural homology to native GLP-1, modified with amino acid substitutions and a C-18 fatty acid chain that enables albumin binding, extending half-life to approximately 7 days. Centrally, it activates anorexigenic POMC/CART neurons and inhibits orexigenic NPY/AgRP neurons in the arcuate nucleus of the hypothalamus, reducing hunger and increasing satiety. Peripherally, it slows gastric emptying, enhances glucose-dependent insulin secretion from pancreatic beta-cells, and reduces glucagon secretion, providing comprehensive metabolic regulation.

Standard Dosing

Research indicates 0.25 mg weekly SC for 4 weeks, escalating to 0.5 mg, then 1.0 mg, then 1.7 mg, then 2.4 mg weekly (FDA weight management protocol). Oral: 3 mg daily for 30 days, then 7 mg, then 14 mg daily.

Timing

SC injection any time of day, with or without food, on the same day each week. Oral: take on empty stomach with no more than 4 oz water, 30+ minutes before first food/drink/medications.

Cycle Duration

Long-term/continuous use. Weight regain occurs upon discontinuation (67% regain within 1 year in trials).

Side Effects

  • Nausea (44% — most common)
  • Vomiting
  • Diarrhea
  • Constipation
  • Abdominal pain
  • Injection site reactions
  • Headache
  • Fatigue
  • Gallbladder events
  • Acute pancreatitis (rare)
  • Potential lean mass loss

Contraindications

  • Personal/family history of medullary thyroid carcinoma
  • Multiple Endocrine Neoplasia type 2 (MEN2)
  • History of pancreatitis
  • Pregnancy (Category X) and breastfeeding
  • Severe GI disease (gastroparesis)
  • End-stage renal disease
  • MEN2 syndrome
  • Pancreatitis
  • Severe renal impairment

Best Stacking Partners

5-Amino-1MQMOTS-cTesofensine (with extreme caution)
B

Telmisartan

Pharmaceuticals

Mechanism

Angiotensin receptor blocker with partial PPAR-delta activity that supports blood-pressure control and metabolic resilience.

Contraindications

  • Pregnancy
  • Monitor renal function and potassium

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →